CODEXIS, INC. (CDXS): Results of Operations and Financial Condition
CODEXIS, INC. (CDXS) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Codexis Reports Second Quarter 2026 Financial Results Reports revenue of $14.9 million for the second quarter of 2026, company reiterates full-year financial guidance Shared new advances in RNA therapeutic manufacturing at TIDES US showing that its ECO Synthesis ® Ma
How this was made
The 30-second read
Why it matters
Traders can update models for 2026 revenue and gross margin ranges, reassess funding risk after the July equity raise, and track the ECO GMP Manufacturing Center retrofit timeline and FDA Emerging Technologies engagement into Q4 2026.
Market read
The filing provides fresh, tradable inputs: Q2 financials, reiterated full-year guidance, and a post-quarter equity raise that extends the cash runway through end-2028, alongside a concrete GMP retrofit milestone schedule.
What to watch
The guidance includes GMP build-out costs, so margin trajectory may be sensitive to retrofit timing and customer product mix; also, R&D and SG&A reductions may reflect cost cuts rather than demand acceleration.
Background
This is an SEC 8-K (Item 2.02) with Exhibit 99.1 covering Codexis Q2 2026 results, business updates around its ECO Synthesis platform, and reiterated 2026 financial guidance.
Ticker impact
Codexis reported Q2 2026 revenue of $14.9M, reiterated 2026 guidance ($72M-$76M), and said cash runway extends through end-2028 after a ~$25M net raise.
Bias modestly positive, with upside sensitivity to any follow-through on GMP retrofit progress and CDMO/clinical-stage manufacturing partnership announcements.
The filing discloses concrete financial metrics (Q2 results), explicit full-year revenue and gross margin ranges, and a new capital raise that increases pro forma cash to ~$80M, reducing funding risk. However, it does not provide new customer contract wins or regulatory outcomes, limiting magnitude.
Market effects
Reinforces investor focus on enzymatic manufacturing platforms for RNAi/siRNA, with emphasis on stereoisomer control and scalable GMP readiness.
Limited; company-specific biotech/manufacturing update with no stated regional macro linkage.
Low; no cross-border regulatory or supply-chain shock described.
Counterpoint
Despite cash strengthening, revenue declined year over year and the ECO GMP facility is not planned for full production until end-2027, so near-term execution risk remains high.
Key entities
- issuerCodexis, Inc.
NASDAQ-listed enzymatic solutions company reporting Q2 2026 results and reiterating 2026 guidance in an SEC 8-K.
- technologyECO Synthesis Manufacturing Platform
Codexis enzymatic manufacturing platform highlighted for enzyme-driven stereoisomer control in siRNA and improved sustainability versus solid-phase synthesis.
- programECO GMP Manufacturing Center
Planned GMP retrofit facility for siRNA material for preclinical and Phase 1 use, with full production capability targeted by end-2027.
- regulatorFDA Emerging Technologies team
Codexis engagement referenced for Q4 2026 regarding product quality, stereoisomer control, and comparability.
